BrightGene Pharmaceutical Co., Ltd.

The main purpose of the study is to investigate the relative bioavailability of the test preparation ferric carboxymaltose injection (specification: 10mL:500mg based on Fe, produced by Borri Pharmaceuticals (Suzhou) Co., Ltd.) and the reference preparation ferric carboxymaltose injection (trade name: Ferinject®, specification: 10mL:500mg based on Fe, produced by Vifor France) in Chinese subjects with iron deficiency anemia after a single intravenous push in the fasting state, analyze the pharmacokinetic parameters of the two preparations, evaluate the bioequivalence of the two preparations in the fasting state, and provide a reference for the application and clinical use of the drug. The secondary purpose of the study is to evaluate the safety of the test preparation and the reference preparation in Chinese subjects with iron deficiency anemia after a single intravenous push of 500mg in the fasting state.

Primary study objective: To evaluate the tolerability and safety of single/multiple use of atropine sulfate eye drops in healthy Chinese adults. Secondary study objective: To evaluate the PK characteristics of single/multiple use of atropine sulfate eye drops in healthy Chinese adults.

Primary objective: To investigate the pharmacokinetic parameters of a single oral dose of 2 mg (fasting/after meals) of the test preparation Dienogest Tablets [Specification: 2 mg, provided by Borri Pharmaceuticals (Suzhou) Co., Ltd., produced by Zhejiang Xianjun Pharmaceutical Co., Ltd.] and the reference preparation Dienogest Tablets (Visanne®/Visanne®, Specification: 2 mg, produced by Bayer Weimar GmbH und Co. KG) in healthy adult female subjects in China, to evaluate the bioequivalence of the two preparations, and to provide a reference for the application and clinical use of the drug. Secondary objective: To evaluate the safety of a single oral dose of 2 mg (fasting/after meals) of the test preparation and the reference preparation in healthy adult female subjects in China.